ATE278803T1 - Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte - Google Patents

Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte

Info

Publication number
ATE278803T1
ATE278803T1 AT99952027T AT99952027T ATE278803T1 AT E278803 T1 ATE278803 T1 AT E278803T1 AT 99952027 T AT99952027 T AT 99952027T AT 99952027 T AT99952027 T AT 99952027T AT E278803 T1 ATE278803 T1 AT E278803T1
Authority
AT
Austria
Prior art keywords
proteasome inhibitor
monitoring
drug effects
inhibitor drug
methods
Prior art date
Application number
AT99952027T
Other languages
English (en)
Inventor
Gopalakrishna R Vaddi
Ross L Stein
Lawrence R Dick
Vito J Palombella
Eric S Lightcap
Peter J Elliott
Julian Adams
Teresa A Mccormack
Stephen J Brand
Dan R Burns
Vincent Chau
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE278803T1 publication Critical patent/ATE278803T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99952027T 1998-10-20 1999-10-19 Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte ATE278803T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10491898P 1998-10-20 1998-10-20
US13138199P 1999-04-28 1999-04-28
PCT/US1999/024356 WO2000023614A1 (en) 1998-10-20 1999-10-19 Method for monitoring proteasome inhibitor drug action

Publications (1)

Publication Number Publication Date
ATE278803T1 true ATE278803T1 (de) 2004-10-15

Family

ID=26802081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99952027T ATE278803T1 (de) 1998-10-20 1999-10-19 Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte

Country Status (15)

Country Link
US (1) US6613541B1 (de)
EP (1) EP1123412B1 (de)
JP (1) JP4503182B2 (de)
KR (1) KR20010080267A (de)
CN (1) CN1331752A (de)
AT (1) ATE278803T1 (de)
AU (1) AU762373B2 (de)
BR (1) BR9914648A (de)
CA (1) CA2347275C (de)
DE (1) DE69920940T2 (de)
ES (1) ES2228118T3 (de)
HK (1) HK1040533A1 (de)
IL (2) IL142647A0 (de)
NZ (1) NZ511197A (de)
WO (1) WO2000023614A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272558T3 (es) 2000-10-12 2007-05-01 Viromics Gmbh Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
DE10051716A1 (de) * 2000-10-12 2002-04-25 Ulrich Schubert Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren
JP4395549B2 (ja) 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
EP1472238B1 (de) * 2002-02-01 2012-07-04 Promega Corporation Biolumineszenz protease assay
DE10316735A1 (de) 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
DE10232902A1 (de) * 2002-07-19 2004-01-29 Bayer Cropscience Ag Verfahren zum Identifizieren von Inhibitoren des 20S und 26S Proteasoms
KR20060026052A (ko) 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
EP2441767B1 (de) 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamide und Verwendungsverfahren dafür
CN1833170B (zh) * 2003-08-08 2011-07-06 霍夫曼-拉罗奇有限公司 蛋白类蛋白酶体激活剂亚基3(pse3)作为结直肠癌标记物的用途
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7416854B2 (en) * 2004-01-22 2008-08-26 Promega Corporation Luminogenic and nonluminogenic multiplex assay
US7553632B2 (en) 2004-01-22 2009-06-30 Promega Corporation Luminogenic and nonluminogenic multiplex assay
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
BRPI0509824A (pt) 2004-04-30 2007-10-09 Nereus Pharmaceuticals Inc compostos heterocìclicos [3.2.0] e métodos de uso dos mesmos
EP2030981B1 (de) * 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Verbindungen zur Proteasome Enzymhemmung
US20060088471A1 (en) * 2004-10-20 2006-04-27 Proteolix, Inc. Compounds for enzyme inhibition
SG157365A1 (en) 2004-12-03 2009-12-29 Dana Farber Cancer Inst Inc Compositions and methods for treating neoplastic diseases
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20060193844A1 (en) * 2005-02-28 2006-08-31 Proteolix, Inc. Methods for enzyme inhibition
JP2009506772A (ja) * 2005-09-01 2009-02-19 プロメガ コーポレイション 細胞ベースの発光及び非発光プロテアソームアッセイ
MY171061A (en) * 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
US20080118940A1 (en) * 2006-11-22 2008-05-22 Maher Albitar Proteasomal peptidase activity and the use thereof in clinical applications
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
AU2008239654A1 (en) 2007-04-13 2008-10-23 Promega Corporation Luminescent live and dead cell assay
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
EP3090737A1 (de) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Kombinationstherapie mit peptidepoxyketonen
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US20110053198A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for proliferative hematological disorders
US20110053199A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
US20110053197A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
JPH08507754A (ja) 1993-02-10 1996-08-20 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Ｍｈｃ−１拘束性抗原提示におけるａｔｐ−ユビキチン依存蛋白分解の役割およびそのインヒビター
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
CA2330210A1 (en) * 1998-06-13 1999-12-23 Zarpex Biosciences Limited Proteasomal activity

Also Published As

Publication number Publication date
DE69920940D1 (de) 2004-11-11
AU6433399A (en) 2000-05-08
US6613541B1 (en) 2003-09-02
CA2347275A1 (en) 2000-04-27
EP1123412A1 (de) 2001-08-16
WO2000023614A1 (en) 2000-04-27
WO2000023614A8 (en) 2000-07-13
IL142647A (en) 2006-04-10
IL142647A0 (en) 2002-03-10
CN1331752A (zh) 2002-01-16
BR9914648A (pt) 2001-11-27
JP4503182B2 (ja) 2010-07-14
CA2347275C (en) 2010-03-09
JP2002527114A (ja) 2002-08-27
NZ511197A (en) 2003-08-29
EP1123412B1 (de) 2004-10-06
KR20010080267A (ko) 2001-08-22
DE69920940T2 (de) 2005-11-17
ES2228118T3 (es) 2005-04-01
AU762373B2 (en) 2003-06-26
HK1040533A1 (zh) 2002-06-14

Similar Documents

Publication Publication Date Title
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
EA200600452A1 (ru) Автоматизированные способы и системы для обнаружения и анализа сосудистых бляшек
ATE227847T1 (de) Teststreifen zur visuellen ermittlung der blutglukose-konzentration
ATE268477T1 (de) Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
MY133942A (en) Reagent test strip for analyte determination having hemolyzing agent
PT821234E (pt) Suporte de teste diagnostico com um campo de teste multicamada e metodo para determinacao de substancias a analisar utilizando o mesmo
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
ES2132272T3 (es) Procedimiento para la determinacion de aductos de hemoglobina.
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
DE60015726D1 (de) Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben
ATE454628T1 (de) Automatisches system und verfahren zur vor-ort- detektion von drogen
ES2061459T3 (es) Procedimiento de ensayo de substancias fisiologicamente activas.
ATE511549T1 (de) Kit zur messung der thrombinerzeugung in einer blut- oder plasmaprobe eines patienten
NO20074610L (no) Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
PT1003458E (pt) Teste de funcao hepatica
DE50010710D1 (de) Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode
ATE254287T1 (de) Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien
ATE302947T1 (de) Verfahren zum nachweis eines lipoprotein- akutphaseprotein-komplexes
DE69221040D1 (de) Aktivätsmessungen des amylin
DE50113202D1 (de) Verfahren zur analyse von stuhlproben für diagnostische zwecke
NO20016080L (no) Analyse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties